Enstilar Foam for Nail Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Enstilar Foam, a medication that combines vitamin D and a steroid, for treating nail psoriasis. The foam is applied to the nails regularly to slow down skin cell growth and reduce inflammation. The study aims to see if this treatment is safe and effective for people with nail psoriasis. Enstilar Foam, a combination of calcipotriol and betamethasone dipropionate, has been used effectively for treating plaque psoriasis and scalp psoriasis.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have been using treatments on the target fingernail in the last 6 months, you may not be eligible.
How does Enstilar Foam differ from other treatments for nail psoriasis?
What data supports the effectiveness of the drug Enstilar Foam for nail psoriasis?
Research shows that Enstilar Foam, which contains calcipotriol and betamethasone, is effective for treating plaque psoriasis, a related skin condition. While specific studies on nail psoriasis are limited, the components of Enstilar Foam have shown positive results in treating psoriasis, suggesting potential benefits for nail psoriasis as well.12567
Who Is on the Research Team?
Boni E Elewski, Dr
Principal Investigator
University of Alabama at Birmingham/Dermatology
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once daily Enstilar Foam (calcipotriene and betamethasone dipropionate) for nail psoriasis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Enstilar Foam
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
LEO Pharma
Industry Sponsor
Christophe Bourdon
LEO Pharma
Chief Executive Officer since 2022
Engineering degree from Université de Technologie de Compiègne
Dr. Siri Torhaug
LEO Pharma
Chief Medical Officer since 2022
MD, PhD